VREOF · Vireo Growth Inc.
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $511.67M | $268.77M | $99.38M | $88.13M | $74.63M | $54.45M | $49.21M | |
| $39.32M | — | — | — | $39.42M | $32.01M | $31.11M | |
| $248.9M | $127.1M | $50.77M | $44.1M | $30.91M | $19.8M | $17.13M | |
| — | 47.29% | 51.09% | 50.04% | 41.42% | 36.36% | 34.8% | |
| $163.79M | $81.19M | $28.06M | $28.22M | $33.82M | $33.66M | $26.37M | |
| $11.95M | $5.75M | $720.13K | $678.86K | $676.57K | $817.22K | $615.09K | |
| $24.11M | $16.11M | $2.54M | $2.87M | $3.34M | $3.03M | $2.48M | |
| $247.24M | $128.14M | $37.21M | $33.52M | $37.85M | $40.28M | $40.17M | |
| $1.65M | -$1.05M | $13.56M | $10.58M | -$6.94M | -$20.48M | -$23.04M | |
| — | -0.39% | 13.65% | 12% | -9.3% | -37.62% | -46.82% | |
| $25.76M | $15.06M | $16.1M | $13.45M | -$3.6M | -$17.45M | -$20.56M | |
| $29.74M | — | $31.19M | $31.26M | $22.59M | $10.58M | $5.1M | |
| -$16.66M | -$38.86M | -$30.46M | -$28.4M | -$29.63M | -$9.09M | $8.89M | |
| -$15.01M | -$39.91M | -$16.89M | -$17.82M | -$36.56M | -$29.57M | -$14.15M | |
| — | $28.23M | $11.11M | $7.72M | $5.89M | $4.12M | $8.79M | |
| -$67.11M | -$68.11M | -$28.01M | -$25.55M | -$42.46M | -$33.69M | -$22.94M | |
| — | -25.34% | -28.18% | -28.99% | -56.89% | -61.88% | -46.62% | |
| USD/shares | -$1.90 | -$2.70 | -$4.80 | -$5.70 | -$9.90 | -$8.10 | -$7.20 |
| USD/shares | -$1.90 | -$2.70 | -$4.80 | -$5.70 | -$9.90 | -$8.10 | -$7.20 |
| shares | — | 24.49M | 6.01M | 4.51M | 4.27M | 4.13M | 3.25M |
| shares | — | 24.49M | 6.01M | 4.51M | 4.27M | 4.13M | 3.25M |
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 47 similar-size Drug Manufacturers - Specialty & Generic companies (of 94 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Retail | $219,933,107 | $79,534,555 | $73,620,866 | $62,123,357 | $44,692,385 | $37,236,301 |
| Wholesale Product | $48,836,161 | $19,849,666 | $14,512,297 | — | — | — |
| Wholesale Product | — | — | — | $12,502,510 | $9,753,783 | $11,972,314 |
| Product And Service Other | — | — | — | — | — | $2,714 |